Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa Chief Executive Officer, and Maged Shenouda Chief Financial Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 7:30am ET at the 2024 Jefferies Global Healthcare Conference in New York, NY . Management will also host one-on-one investor meetings. Please find additional details about the event below.

2024 Jefferies Global Healthcare Conference
Format: Fireside chat
Presentation Date: Thursday, June 6, 2024 , 7:30am ET
Webcast: Click Here

Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors . An archived replay will be available for 30 days following the conclusion of the event.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-2024-jefferies-global-healthcare-conference-302161512.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Relmada Therapeutics Inc.RLMD NASDAQ:RLMD Base Metals Investing

RLMD

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024 at 11:20am ET . Management will also host one-on-one investor meetings. Please find additional details about the event below.

2024 Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Presentation Date: Wednesday, June 12, 2024 , 11:20am ET
Webcast: Click Here

Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Goldman Sachs representative to schedule a meeting.

The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors . An archived replay will be available for 90 days following the conclusion of the event.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302167986.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024 . The Company will host a conference call today, Wednesday, May 8, at 4:30 PM Eastern Time 1:30 PM Pacific Time .

"Enrollment continues to advance in our ongoing Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD)," said Sergio Traversa , Relmada's Chief Executive Officer. "As such, we continue to expect that the Reliance II study (study 302) will be fully enrolled with top-line data anticipated in the second half of 2024. In addition, we continue to enroll in our second ongoing Phase 3 trial of REL-1017, Relight (study 304)."

"We also continue to plan for the initiation of a single-ascending dose Phase 1 trial for our promising preclinical novel modified-release psilocybin in obese patients, which is anticipated to commence in the first half of this year. The goal of this study will be to define the pharmacokinetic, safety and tolerability profile of our modified-release psilocybin formulation in this population, and it will be followed by a Phase 2a trial to establish clinical proof-of-concept," continued Mr. Traversa.

Upcoming Anticipated Milestones

Complete enrollment in the ongoing Reliance II study, which is planned to enroll approximately 300 patients, with top-line data in the second half of 2024.
Commence a Phase 1 trial in obese patients in the first half of 2024 to define the pharmacokinetic, safety and tolerability profile of the Company's modified-release psilocybin formulation (REL-P11), followed by a Phase 2a trial to establish clinical proof-of-concept with data expected in the first half of 2025.

First Quarter 2024 Financial Results

Research and development expense for the three months ended March 31, 2024 , totaled $13.3 million , compared to $15.9 million for the three months ended March 31, 2023 . The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310).
General and administrative expense for the three months ended March 31, 2024 , totaled $9.7 million compared to $12.3 million for the three months ended March 31, 2023 , a decrease of approximately $2.6 million . The decrease was primarily driven by a decrease in stock-based compensation expense.
Net cash used in operating activities for the three months ended March 31, 2024 , totaled $13.0 million compared to $16.5 million for the three months ended March 31, 2023 .
The net loss for the three months ended March 31, 2024 , was $21.8 million , or $0.72 per basic and diluted share, compared with a net loss of $26.4 million , or $0.87 per basic and diluted share, for the three months ended March 31, 2023 .
As of March 31, 2024 , the Company had cash, cash equivalents, and short-term investments of approximately $83.6 million , compared to cash, cash equivalents, and short-term investments of approximately $96.3 million at December 31, 2023 .

Conference Call and Webcast Details

*Wednesday, May 8 ^th @ 4:30pm ET*
Toll Free:		888-886-7786
International:		416-764-8658
Conference ID:		38754189
Webcast:		CLICK HERE

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About REL-P11

Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. The pleiotropic metabolic effects of low-dose psilocybin were discovered while studying its neuroplastogen™ potential in a rodent model deficient in neurogenesis – obese rats maintained on a high fructose, high fat diet (HFHFD), and were then replicated in mice.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

Relmada Therapeutics, Inc. Consolidated Balance Sheets (Unaudited)

	As of
	March 31,		As of
	2024 (Unaudited)		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	1,335,018	$	4,091,568
Short-term investments		82,277,687		92,232,292
Prepaid expenses		752,334		1,185,057
Total current assets		84,365,039		97,508,917
Other assets		43,125		43,125
Total assets	$	84,408,164	$	97,552,042

Commitments and Contingencies (See Note 6)

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable	$	5,189,101	$	3,506,009
Accrued expenses		7,172,732		8,688,791
Total current liabilities		12,361,833		12,194,800
Total liabilities		12,361,833		12,194,800

Stockholders' Equity:
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding		-		-
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding		-		-
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,174,202 and 30,099,203 shares issued and outstanding, respectively		30,174		30,099
Additional paid-in capital		654,746,964		646,229,824
Accumulated deficit		(582,730,807)		(560,902,681)
Total stockholders' equity		72,046,331		85,357,242
Total liabilities and stockholders' equity	$	84,408,164	$	97,552,042

Relmada Therapeutics, Inc. Consolidated Statements of Operations (Unaudited)

	Three months ended
	March 31,
	2024		2023

Operating expenses:
Research and development	$	13,305,306	$	15,861,010
General and administrative		9,682,554		12,292,599
Total operating expenses		22,987,860		28,153,609

Loss from operations		(22,987,860)		(28,153,609)

Other income (expenses):
Interest/investment income, net		1,055,888		1,207,631
Realized gain (loss) on short-term investments		53,133		(666,708)
Unrealized gain on short-term investments		50,713		1,291,110
Total other income (expenses)		1,159,734		1,832,033

Net loss	$	(21,828,126)	$	(26,321,576)

Loss per common share – basic and diluted	$	(0.72)	$	(0.87)

Weighted average number of common shares outstanding – basic and diluted		30,132,170		30,099,203

Relmada Therapeutics, Inc. Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

	Three months ended March 31, 2024
	Common Stock				Additional Paid-in		Accumulated
	Shares		Par Value		Capital		Deficit		Total
Balance - December 31, 2023		30,099,203	$	30,099	$	646,229,824	$	(560,902,681)	$	85,357,242
Stock based compensation		-		-		8,295,468		-		8,295,468
Options exercised for common stock		74,999		75		246,672		-		246,747
ATM Fees		-		-		(25,000)		-		(25,000)
Net loss		-		-		-		(21,828,126)		(21,828,126)
Balance – March 31, 2024		30,174,202	$	30,174	$	654,746,964	$	(582,730,807)	$	72,046,331

	Three months ended March 31, 2023
	Common Stock				Additional Paid-in		Accumulated
	Shares		Par Value		Capital		Deficit		Total
Balance - December 31, 2022		30,099,203	$	30,099	$	602,517,138	$	(462,110,935)	$	140,436,302
Stock based compensation		-		-		11,354,466		-		11,354,466
Net loss		-		-		-		(26,321,576)		(26,321,576)
Balance - March 31, 2023		30,099,203	$	30,099	$	613,871,604	$	(488,432,511)	$	125,469,192

Relmada Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

	Three months ended
	March 31,
	2024		2023

Cash flows from operating activities
Net loss	$	(21,828,126)	$	(26,321,576)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		8,295,468		11,354,466
Realized (gain) loss on short-term investments		(53,133)		666,708
Unrealized gain on short-term investments		(50,713)		(1,291,110)
Change in operating assets and liabilities:
Other receivables		-		512,432
Prepaid expenses		432,723		945,606
Accounts payable		1,683,092		(839,971)
Accrued expenses		(1,516,059)		(1,531,649)
Net cash used in operating activities		(13,036,748)		(16,505,094)

Cash flows from investing activities
Purchase of short-term investments		(7,013,933)		(34,767,287)
Sale of short-term investments		17,072,384		74,770,836
Net cash provided by investing activities		10,058,451		40,003,549

Cash flows from financing activities
Proceeds from options exercised for common stock		246,747		-
ATM Fees		(25,000)		-
Net cash provided by financing activities		221,747		-
Net increase in cash and cash equivalents		(2,756,550)		23,498,455
Cash and cash equivalents at beginning of the period		4,091,568		5,395,905

Cash and cash equivalents at end of the period	$	1,335,018	$	28,894,360

View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-results-302140410.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024 . The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday May 8, 2024.

Live Conference Call & Webcast:
Toll Free:	888-886-7786
International:	416-764-8658
Conference ID:	38754189
Webcast:	Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully initiated and carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-first-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-may-8-2024-302136383.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Forte Minerals Completes Miscanthus Acquisition from Globetrotters Resource Group

Forte Minerals Corp. ("Forte"or the"Company") (CSE:CUAU)(OTCQB:FOMNF)(Frankfurt:2OA), a Canadian exploration company focused on developing copper and gold assets in Peru, is pleased to announce the completion of its acquisition of the Miscanthus Property (the "Property") a high-sulphidation epithermal gold-silver and porphyry copper-molybdenum-gold prospect in central Peru from Globetrotters Resource Group Inc. ("Globetrotters"), as initially announced on October 23, 2024

The Property consists of 4 Concessions: Totaling 3,200 hectares, which was transferred to Forte's Peruvian subsidiary, Cordillera Resources Perú S.A.C and includes an approved DIA drilling permit for up to 40 platforms over 172 hectares, significantly lowering permitting risk.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Red Metal Resources Provides Corporate Update and Announces Financing

Red Metal Resources Ltd. (CSE: RMES) (OTC Pink: RMESF) (FSE: I660) ("Red Metal" or the "Company") is pleased to provide a corporate update and announce a financing.

Red Metal has executed a Definitive Agreement on claims in Quebec, see news release dated October 30, 2024, and Company views these claims as a foundation. Red Metal intends to expand and grow the mineral claims that are within the Timiskaming Graben Formation near the town of Ville Marie. Meanwhile, the Company will look to continue its work on its flagship post discovery copper project in Chile.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bold Ventures Receives Assays up to 16.3 gpt Au at its Wilcorp Property

Bold Ventures Inc. (TSXV: BOL) (the "Company" or "Bold") announces that it has received assays ranging from

The 16.3 gpt Au sample corresponds to a 10 cm quartz vein in an old pit and stripped area, 35 meters northeast of a 2012 sample which returned 14.4 gpt Au. Additional sampling 100 meters further south yielded gold results up to 892 ppb Au from intermediate schist with quartz-ankerite veining in outcrop, 25 meters west of a 2012 sample which returned 462 ppb Au. An angular boulder of intermediate schist with quartz veining 45 meters east of the 2012 sample returned 110 ppb Au. See Figure 1 for thematic Au results across the property to date, and Table 1 below for sample descriptions and all Au results from the site visit.

Sample	Date	Area	X (UTM Z15)	Y (UTM Z15)	Source	Description	Assay Certificate No.	Au_ppb
B414851	2024-09-08	Northern Trenches 2012 14 grammer	615815	5403873	Outcrop	Qtz-ankerite vein in silicified mafic schist, tr-1% arsenopyrite.	A24-10868	16300
B414852	2024-09-08	Northern Trenches 2012 14 grammer	615772	5403836	Outcrop	Qtz-ankerite vein.	A24-10868	307
B414853	2024-09-08	Bjorkman 2012 1/2 grammer	615833	5403777	Outcrop	Silicified mafic schist.	A24-10868	23
B414854	2024-09-08	Bjorkman 2012 1/2 grammer	615833	5403776.7	Outcrop	Quartz sericite schist.	A24-10868	2.5
B414855	2024-09-08	Bjorkman 2012 1/2 grammer	615833	5403773	Talus	Quartz sericite schist.	A24-10868	2.5
B414856	2024-09-08	Bjorkman 2012 1/2 grammer	615827	5403772	Frost heave	Silicified quartz sericite schist.	A24-10868	2.5
B414857	2024-09-08	Bjorkman 2012 1/2 grammer	615838	5403773	Frost heave	Silicified quartz sericite schist.	A24-10868	2.5
B414858	2024-09-08	Bjorkman 2012 1/2 grammer	615827	5403768	Outcrop	Intermediate schist with moderate qtz-ankerite veins.	A24-10868	892
B414859	2024-09-08	Bjorkman 2012 1/2 grammer	615840	5403764	Frost heave	Silicified quartz sericite schist.	A24-10868	2.5
B414860	2024-09-08	Bjorkman 2012 1/2 grammer	615844	5403760	Frost heave	Silicified quartz sericite schist.	A24-10868	2.5
B414861	2024-09-08	Bjorkman 2012 1/2 grammer	615845	5403764	Outcrop	Quartz-ankerite vein.	A24-10868	2.5
B414862	2024-09-08	Bjorkman 2012 1/2 grammer	615850	5403765	Frost heave	Silicified quartz sericite schist with moderate qtz veinlets, minor pyrite, chalcopyrite.	A24-10868	2.5
B414863	2024-09-08	Bjorkman 2012 1/2 grammer	615896	5403771	Angular boulder	Silicified intermediate schist, ankerite alteration, min-mod quartz stringers.	A24-10868	110
B414873	N/A	N/A	N/A	N/A	N/A	Blank.	A24-10868	2.5
B414874	N/A	N/A	N/A	N/A	N/A	Standard CDN-GS-2G.	A24-10868	2260

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Vertex Minerals Limited Quarterly Activities Report

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) has identified major benefits for utilising pre-concentration technology at its Reward high grade gold mine.

Ore sorting pre-concentration test work was initiated with leading ore sorting provider TOMRA with outstanding results.

94kg of sample from the low-grade stockpile at Reward Gold Mine (Reward) was sorted. The following results were reported;

- Head grade to Sorter weighted average grade (WAG) = 3.70 g/t gold,

- Ore grade WAG after sorting = 16.22g/t gold (337.20% increase on grade),

- Ore/waste split after sorting = 19.31kgs Ore vs 74.54kgs Waste (79% mass reduction),

- Gold lost to waste fraction = 0.03grams (>90% efficiency)

Refurbishment of the plant is well underway, and Vertex anticipates that the plant will be re-installed at Hill End later this year. The Company anticipates production will commence in January 2025.

Vertex acquired a Boart Longyear LM90 underground drill rig to advance exploration at the Reward gold mine below the existing resource.

ORE SORTER TEST WORK AND IMPLEMENTATION INTO THE HILL END GRAVITY PLANT

Pre-concentration technology initiated at the Hill End Gravity Plant to separate highgrade ore from waste before it enters the processing plant.

By processing only high-grade ore, energy consumption can be reduced, water consumption will be halved leading to lower operating costs and reduction of the carbon footprint.

The small sorting unit will be simply incorporated in the existing plant being refurbished by Gekko.

Previous scoping test results from TOMRA suggested that the Greywacke country rock can be efficiently and effectively separated from the high-grade quartz carrying the gold leading to significant head grade uplift and reduced material to be processed.

Test Results

94kg of sample from the low-grade stockpile at Reward Gold Mine (Reward) was sorted.

The following results are reported;

- Head grade to Sorter weighted average grade (WAG) = 3.70 g/t gold,

- Ore grade WAG after sorting = 16.22g/t gold (337.20% increase on grade),

- Ore/waste split after sorting = 19.31kgs Ore vs 74.54kgs Waste (79% mass reduction),

- Gold lost to waste fraction = 0.03grams (>90% efficiency)

ACQUISITION OF A LM90 UNDERGROUND DRILL RIG

Vertex has acquired a Boart Longyear LM90 underground drill rig to advance exploration at the Reward gold mine below the existing resource.

The Vertex team are planning diamond drill programs for the following:

- Below the current JORC-2012 Reward Resource with the aim of expanding upon the existing resource;

- Fosters Exploration Target; and

- South Star prospect area

Acquisition of the LM90 follows an extensive review of the mineralisation potential below the Reward resource, which has only been drilled up to 50m below the Amalgamated Adit. This area targeted is referred to as the 'Reward mid depths' as it is located just 80m to ~200m below the Amalgamated Adit. Refer to Figure 1*

Upon commissioning of the LM90 drill rig, Vertex have planned eight drill holes to target the high-grade Fosters Exploration target.

The LM90 has several advantages well-suited to Vertex's requirements, including:

- The ability to work on surface and underground;

- Safe, Semi-automated, with a rod-handler system which allows for less manual handling;

- Allows greater flexibility in drilling over a number of resource and exploration areas; and

- LM 90 rigs are well-established in the industry as safe and reliable underground drill rigs.

Vertex acquiring its own rig has many advantages;

- Per-metre drill costs will be significantly less than hiring an external drill contractor

- More control and accuracy over precision of drilling.

- Works well with Job sharing

- Reduces pressure on Mining crew to have drill cuddy availability

- The LM90 rig will be accounted for as an asset on the Vertex balance sheet

*To view the full quarterly report, please visit:
https://abnnewswire.net/lnk/CHF6G92O

About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.

Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
MANN WEST
MAN24-33	11.2	396.0	384.8	0.24	0.011	0.009	0.008	0.35	6.48	0.028
including	174.0	183.0	9.0	0.30	0.014	0.018	0.011	0.18	6.34	0.100
MAN24-37	8.7	180.0	171.3	0.26	0.011	0.005	0.006	0.15	6.04	0.037
and	236.4	402.0	165.6	0.26	0.012	0.008	0.007	0.24	6.26	0.071
including	267.0	273.0	6.0	0.37	0.013	0.004	0.005	0.30	7.73	0.100
and	361.5	369.0	7.5	0.38	0.013	0.078	0.043	0.18	6.35	0.162
MAN24-45	6.2	402.0	395.8	0.24	0.013	0.016	0.010	0.39	6.60	0.235
including	136.5	144.0	7.5	0.30	0.014	0.044	0.015	0.75	6.99	0.086
MAN24-49	5.4	198.2	192.8	0.19	0.013	0.029	0.017	0.41	7.44	0.081
and	221.6	402.0	180.4	0.21	0.011	0.003	0.006	0.42	6.69	0.033
MAN24-54	49.5	192.8	143.3	0.26	0.011	0.003	0.003	0.13	5.80	0.045
and	216.5	402.0	185.5	0.27	0.012	0.012	0.007	0.28	6.22	0.029
including	268.5	277.5	9.0	0.48	0.019	0.003	0.003	0.62	7.86	0.015
MAN24-58	21.0	351.0	330.0	0.26	0.013	0.015	0.007	0.24	6.51	0.076
including	193.5	204.5	11.0	0.35	0.015	0.023	0.009	0.44	6.86	0.110
and	307.5	321.0	13.5	0.36	0.016	0.040	0.018	0.19	7.17	0.130
MAN24-62	8.6	501.0	492.4	0.18	0.014	0.041	0.026	0.31	7.88	0.047
MAN24-69	7.2	229.5	222.3	0.19	0.013	0.022	0.015	0.38	7.35	0.054
and	264.0	491.0	227.0	0.19	0.013	0.004	0.005	0.41	7.35	0.023
MAN24-71	23.5	260.5	237.0	0.27	0.012	0.011	0.009	0.25	6.29	0.082
including	63.0	108.0	45.0	0.37	0.013	0.036	0.018	0.15	5.77	0.196
and	302.2	501.0	198.8	0.17	0.012	0.014	0.032	0.36	7.56	0.027

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
MAN24-19	3.0	304.0	301.0	0.18	0.012	0.008	0.006	0.42	7.36	0.037
and	384.0	396.8	12.8	0.18	0.010	0.003	0.008	0.33	6.29	0.083
MAN24-22	9.0	552.0	543.0	0.24	0.012	0.005	0.006	0.17	5.90	0.057
Including	195.0	207.0	12.0	0.29	0.013	0.022	0.008	0.14	5.66	0.082
MAN24-26	12.0	55.5	43.0	0.25	0.011	0.003	0.008	0.18	5.85	0.101
and	100.5	399.0	298.5	0.23	0.011	0.004	0.003	0.16	6.22	0.052
MAN24-32	90.0	402.0	312.0	0.21	0.015	0.004	0.004	0.27	6.42	0.121
including	96.0	99.3	3.3	1.03	0.308	0.026	0.013	0.14	19.78	4.840
MAN24-34	75.0	259.0	184.0	0.22	0.011	0.008	0.008	0.31	6.79	0.044
and	297.0	402.0	105.0	0.24	0.011	0.007	0.008	0.22	5.97	0.080
MAN24-35	25.2	144.3	119.1	0.22	0.012	0.003	0.004	0.24	6.74	0.051
and	161.0	387.0	226.0	0.18	0.013	0.005	0.006	0.40	7.39	0.030
MAN24-39	97.5	171.0	73.5	0.19	0.011	0.007	0.007	0.45	7.28	0.049
MAN24-40	103.3	153.0	49.7	0.24	0.012	0.004	0.004	0.26	6.10	0.071
and	141.0	396.0	255.0	0.21	0.012	0.005	0.005	0.41	7.05	0.031
MAN24-43	76.7	182.4	105.7	0.22	0.012	0.005	0.006	0.22	6.37	0.114
and	205.4	402.0	196.6	0.23	0.012	0.003	0.005	0.38	6.56	0.033
MAN24-44	43.0	186.7	143.7	0.21	0.011	0.004	0.004	0.30	6.65	0.029
and	195.0	402.0	207.0	0.19	0.013	0.005	0.007	0.415	7.176	0.030
MAN24-52	11.4	46.7	35.3	0.31	0.037	0.003	0.006	0.169	5.794	0.176
and	73.0	400.0	327.0	0.20	0.013	0.004	0.005	0.390	6.779	0.028
MAN24-56B	45.0	402.0	357.0	0.20	0.013	0.003	0.005	0.411	7.126	0.022
MAN24-60	31.9	241.2	209.3	0.20	0.013	0.007	0.007	0.369	6.920	0.060
and	277.5	310.9	33.4	0.26	0.015	0.003	0.004	0.055	8.981	0.057

Hole ID	From (m)	To (m)	Length (m)*	Ni %	Co %	Pd g/t	Pt g/t	Cr %	Fe %	S %
MAN24-24	39.0	109.5	70.5	0.15	0.010	0.004	0.003	0.43	6.77	0.061
MAN24-31	28.4	519.0	490.6	0.18	0.012	0.013	0.022	0.38	6.88	0.061
including	57.0	72.0	15.0	0.30	0.014	0.044	0.024	0.28	6.47	0.280
MAN24-36	21.0	408.0	387.0	0.21	0.012	0.012	0.010	0.50	6.93	0.063
MAN24-46	18.8	312.5	293.7	0.17	0.012	0.005	0.007	0.40	7.54	0.028
and	327.9	399.0	71.1	0.17	0.014	0.012	0.008	0.39	8.25	0.057
MAN24-47	18.0	402.0	384	0.18	0.012	0.006	0.008	0.48	7.36	0.035
MAN24-50	21.5	280.6	259.1	0.15	0.012	0.004	0.005	0.45	7.54	0.024
and	313.5	390.0	76.5	0.18	0.013	0.010	0.011	0.41	7.29	0.051
MAN24-51	45.0	171.0	126	0.16	0.013	0.008	0.010	0.44	7.76	0.030
and	196.0	402.0	206	0.16	0.012	0.005	0.005	0.34	7.25	0.032
MAN24-53	15.0	402.0	387	0.11	0.012	0.007	0.010	0.33	8.07	0.032
MAN24-55	17.4	177.8	160.4	0.18	0.013	0.005	0.005	0.53	7.56	0.046
and	352.5	402.0	49.5	0.19	0.012	0.007	0.017	0.36	6.67	0.039
MAN24-59	31.5	402.0	370.5	0.15	0.012	0.010	0.011	0.38	7.19	0.044
MAN24-63	132.5	267.0	134.5	0.20	0.012	0.019	0.016	0.38	7.34	0.072
including	142.5	156.0	13.5	0.34	0.012	0.060	0.031	0.14	7.20	0.020
and	311.2	462.0	150.8	0.18	0.012	0.005	0.006	0.43	7.20	0.024
MAN24-67	15.6	420.0	404.4	0.15	0.012	0.025	0.021	0.36	7.72	0.039
including	327.0	348.0	21.0	0.23	0.013	0.081	0.043	0.55	7.79	0.141

Hole ID	From (m)	To (m)	Length (m)	Pt+Pd (g/t)	Pd g/t)	Pt (g/t)	Ni (%)	Co (%)	Cr (%)	Fe (%)	S (%)
MAN24-49	201.0	219.0	18.0	0.51	0.30	0.21	0.04	0.007	0.37	4.58	0.021
MAN24-62	309	327	18.0	0.44	0.31	0.13	0.18	0.015	0.49	8.11	0.054
MAN24-35	390.0	402.0	12.0	0.33	0.11	0.22	0.06	0.011	0.48	7.49	0.014
MAN24-60	242.1	265.5	23.4	0.43	0.25	0.18	0.03	0.007	0.36	5.01	0.014
and	345.0	360.0	15.0	0.42	0.26	0.16	0.03	0.007	0.34	5.41	0.015
MAN24-69	238.0	255.0	17.0	0.45	0.26	0.19	0.04	0.007	0.39	4.76	0.013
MAN24-31	118.5	131.2	12.7	0.58	0.22	0.36	0.03	0.007	0.28	4.55	0.012
MAN24-38	125.0	138.0	13.0	0.32	0.21	0.11	0.02	0.007	0.28	6.79	0.024
and	285.0	292.6	7.6	0.47	0.21	0.26	0.05	0.011	0.29	6.21	0.013
and	382.5	396.2	13.7	0.39	0.18	0.21	0.05	0.012	0.36	5.64	0.018
MAN24-46	312.5	327.9	15.4	0.46	0.24	0.22	0.04	0.008	0.37	5.33	0.008
MAN24-50	280.6	297.3	16.7	0.50	0.33	0.17	0.03	0.007	0.38	5.07	0.011
MAN24-51	171.0	186.0	15.0	0.31	0.20	0.12	0.02	0.007	0.27	6.74	0.042
MAN24-55	288.0	337.0	49.0	0.33	0.17	0.17	0.02	0.007	0.25	6.33	0.038
MAN24-63	292.5	303.0	10.5	0.33	0.21	0.12	0.02	0.007	0.27	6.97	0.019

Hole ID	From (m)	To (m)	Length (m)	Au (g/t)
MAN24-19	382.5	384.0	1.5	0.40
MAN24-24	52.5	67.5	15.0	0.32
MAN24-31	57.0	58.5	1.5	0.41
MAN24-36	348.0	354.0	6.0	0.60
including	348.0	349.5	1.5	1.58
MAN24-51	289.5	304.5	15.0	0.36
Including	300.0	301.5	1.5	1.06
MAN24-55	396.0	399.0	3.0	0.36
MAN24-59	139.5	141.0	1.5	0.51
and	274.5	276.0	1.5	0.98
MAN24-67	115.5	160.5	45.0	0.45
including	118.5	121.5	3.0	1.15
and	147.0	151.5	4.5	2.36

Hole ID	Easting (mE)	Northing (mN)	Azimuth (⁰)	Dip (⁰)	Length (m)
REID
REI24-41	457554	5404310	0	-60	706
REI24-43	457350	5404200	70	-60	696
REI24-45	457859	5403898	90	-60	668
REI24-46	456306	5404370	180	-50	702
REI24-47	457765	5404100	90	-60	702
REI24-48	456860	5404060	180	-55	702
REI24-50	457817	5404256	90	-60	600
REI24-52	457350	5404200	180	-60	759
MANN WEST
MAN24-33	496260	5412289	35	-50	396
MAN24-37	496144	5412134	35	-50	402
MAN24-45	495656	5412189	40	-50	402
MAN24-49	495656	5412189	230	-50	402
MAN24-54	495796	5412336	40	-50	402
MAN24-58	495641	5412486	40	-65	351
MAN24 - 62	495296	5412441	50	-50	501
MANN CENTRAL
MAN24-19	496800	5410400	0	-50	397
MAN24-22	498724	5410530	350	-50	552
MAN24-26	498360	5410370	0	-50	399
MAN24-32	498466	5410751	180	-50	402
MAN24-34	498970	5410764	165	-50	402
MAN24-35	497509	5410702	180	-50	402
MAN24-39	498466	5410751	215	-55	171
MAN24-40	497698	5410729	180	-50	396
MAN24-43	498265	5410644	180	-50	402
MAN24-44	497880	5410638	180	-50	402
MAN24-52	498450	5410430	180	-50	400
MAN24-56B	498260	5410430	180	-50	402
MAN24-60	498445	5410230	180	-50	360
MANN NORTH
MAN24-24	496342	5414290	20	-50	237
MAN24-31	497243	5413464	20	-50	519
MAN24-36	497022	5413872	20	-50	408
MAN24-46	497195	5413805	200	-50	402
MAN24-47	497340	5413730	20	-50	402
MAN24-50	497552	5413697	200	-50	402
MAN24-51	497277	5414004	200	-50	402
MAN24-53	497727	5413538	20	-50	402
MAN24-55	496866	5413943	20	-50	402
MAN24-59	496917	5414076	20	-50	402
MAN24-67	496599	5414301	20	-50	420
REAUME
REU24-11	488435	5422086	90	-50	501
REU24-12	488424	5421854	90	-50	561
REU24-14	488077	5422433	45	-50	402

Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

Latest News

Latest Press Releases

Related News

TOP STOCKS